Protalix Biotherapeutics Stock Performance
| PLX Stock | USD 2.91 0.18 6.59% |
On a scale of 0 to 100, Protalix Biotherapeutics holds a performance score of 11. The company holds a Beta of 0.81, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Protalix Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Protalix Biotherapeutics is expected to be smaller as well. Please check Protalix Biotherapeutics' potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Protalix Biotherapeutics' historical price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 6.23 | Five Day Return 39.42 | Year To Date Return 66.67 | Ten Year Return (63.75) | All Time Return (99.66) |
Last Split Factor 1:10 | Dividend Date 2019-12-20 | Last Split Date 2019-12-20 |
1 | Acquisition by Shaaltiel Yoseph of 122162 shares of Protalix Biotherapeutics at 0.001 subject to Rule 16b-3 | 11/07/2025 |
2 | Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | 11/13/2025 |
3 | Zacks Small Cap Has Bearish Outlook for PLX FY2025 Earnings | 11/19/2025 |
4 | Plantibodies Market Analysis Report 2025 Growing Opportunities in Cost-effective and Scalable Production with Reduced Pathogen Risks - Global Forecast to 2030 | 12/02/2025 |
5 | Protalix, Secarna in agreement to develop rare kidney disorder therapies | 12/17/2025 |
6 | PLX Secarnas Antisense Oligonucleotide Discovery Collaboration | 12/22/2025 |
7 | Protalix outlines 2026 rare-disease growth and pipeline strategy - TipRanks | 01/05/2026 |
8 | Aug Action Will Protalix BioTherapeutics Inc benefit from government policy - baoquankhu1.vn | 01/14/2026 |
9 | Analyzing Protalix BioTherapeutics and SQZ Biotechnologies | 01/21/2026 |
10 | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio in the ... | 01/30/2026 |
11 | PLX CHMP Delivers Positive Opinion | 02/03/2026 |
| Begin Period Cash Flow | 23.6 M | |
| Total Cashflows From Investing Activities | 4.2 M |
Protalix Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 219.00 in Protalix Biotherapeutics on November 7, 2025 and sell it today you would earn a total of 72.00 from holding Protalix Biotherapeutics or generate 32.88% return on investment over 90 days. Protalix Biotherapeutics is generating 0.5387% of daily returns assuming volatility of 3.8649% on return distribution over 90 days investment horizon. In other words, 34% of stocks are less volatile than Protalix, and above 90% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Protalix Biotherapeutics Target Price Odds to finish over Current Price
The tendency of Protalix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.91 | 90 days | 2.91 | near 1 |
Based on a normal probability distribution, the odds of Protalix Biotherapeutics to move above the current price in 90 days from now is near 1 (This Protalix Biotherapeutics probability density function shows the probability of Protalix Stock to fall within a particular range of prices over 90 days) .
Protalix Biotherapeutics Price Density |
| Price |
Predictive Modules for Protalix Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protalix Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Protalix Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Protalix Biotherapeutics is not an exception. The market had few large corrections towards the Protalix Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protalix Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protalix Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.23 | |
β | Beta against Dow Jones | 0.81 | |
σ | Overall volatility | 0.24 | |
Ir | Information ratio | 0.06 |
Protalix Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protalix Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protalix Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Protalix Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Latest headline from finance.yahoo.com: PLX CHMP Delivers Positive Opinion |
Protalix Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protalix Stock often depends not only on the future outlook of the current and potential Protalix Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protalix Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 81.1 M | |
| Cash And Short Term Investments | 34.8 M |
Protalix Biotherapeutics Fundamentals Growth
Protalix Stock prices reflect investors' perceptions of the future prospects and financial health of Protalix Biotherapeutics, and Protalix Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protalix Stock performance.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0553 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 187.9 M | ||||
| Shares Outstanding | 80.42 M | ||||
| Price To Earning | (1.23) X | ||||
| Price To Book | 4.15 X | ||||
| Price To Sales | 3.77 X | ||||
| Revenue | 53.4 M | ||||
| Gross Profit | 35.58 M | ||||
| EBITDA | 6.52 M | ||||
| Net Income | 2.93 M | ||||
| Cash And Equivalents | 19.76 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 5.53 M | ||||
| Current Ratio | 1.33 X | ||||
| Book Value Per Share | 0.66 X | ||||
| Cash Flow From Operations | 8.67 M | ||||
| Earnings Per Share | 0.08 X | ||||
| Market Capitalization | 233.22 M | ||||
| Total Asset | 73.42 M | ||||
| Retained Earnings | (378.39 M) | ||||
| Working Capital | 34.46 M | ||||
| Current Asset | 59.65 M | ||||
| Current Liabilities | 10.33 M | ||||
About Protalix Biotherapeutics Performance
Evaluating Protalix Biotherapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protalix Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protalix Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 366.66 | 501.14 | |
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.07 | 0.08 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.06 | 0.06 |
Things to note about Protalix Biotherapeutics performance evaluation
Checking the ongoing alerts about Protalix Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protalix Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protalix Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Latest headline from finance.yahoo.com: PLX CHMP Delivers Positive Opinion |
- Analyzing Protalix Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protalix Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protalix Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protalix Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protalix Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protalix Biotherapeutics' stock. These opinions can provide insight into Protalix Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.